Academic Journal
Integrated Bioinformatics and Experimental Validation to Identify Shared Sialylation-Related Signatures in Emphysematous and Fibrotic Lung Disease.
| Τίτλος: | Integrated Bioinformatics and Experimental Validation to Identify Shared Sialylation-Related Signatures in Emphysematous and Fibrotic Lung Disease. |
|---|---|
| Συγγραφείς: | Wang Y; Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China., Cao K; Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China., Zhao W; Department of Occupational Medicine and Toxicology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. |
| Πηγή: | FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2026 Sep 30; Vol. 40 (18), pp. e72302. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Federation of American Societies for Experimental Biology Country of Publication: United States NLM ID: 8804484 Publication Model: Print Cited Medium: Internet ISSN: 1530-6860 (Electronic) Linking ISSN: 08926638 NLM ISO Abbreviation: FASEB J Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2020- : [Bethesda, Md.] : Hoboken, NJ : Federation of American Societies for Experimental Biology ; Wiley Original Publication: [Bethesda, Md.] : The Federation, [c1987- |
| Ιατρικοί όροι (MeSH): | Pulmonary Emphysema*/metabolism , Pulmonary Emphysema*/genetics , Pulmonary Emphysema*/pathology , Computational Biology*/methods , Idiopathic Pulmonary Fibrosis*/metabolism , Idiopathic Pulmonary Fibrosis*/genetics , Sialyltransferases*/metabolism , Sialyltransferases*/genetics , Pulmonary Fibrosis*/metabolism , Pulmonary Fibrosis*/genetics , Pulmonary Fibrosis*/pathology, Humans ; Animals ; Mice ; Transcriptome |
| Περίληψη: | Emphysema and pulmonary fibrosis represent distinct patterns of chronic lung remodeling but may share molecular and cellular abnormalities. In this study, we analyzed public transcriptomic datasets of chronic obstructive pulmonary disease, emphysema, and idiopathic pulmonary fibrosis from the Gene Expression Omnibus database to explore shared disease-related signatures. Weighted gene co-expression network analysis and differential expression analysis were used to identify common molecular alterations, followed by functional enrichment, protein-protein interaction network construction, hub gene screening, immune infiltration analysis, transcription factor prediction, and single-cell RNA-sequencing validation. The integrated analysis revealed overlapping signatures related to cell adhesion, extracellular matrix organization, vascular regulation, immune responses, and epithelial homeostasis. Five hub genes were validated, and ST6GALNAC5 was further prioritized because of its association with sialylation and predominant enrichment in epithelial cells. Given that sialylation has been rarely investigated in pulmonary fibrosis and emphysema, we therefore further investigated ST6GALNAC5-related epithelial sialylation. Experimental validation on tissue samples showed reduced Sambucus nigra agglutinin lectin signals and decreased ST6GALNAC5 expression in lungs with coexisting emphysematous and fibrotic injury. In vitro experiments confirmed that ST6GALNAC5 overexpression attenuated bleomycin-induced epithelial cell injury. Together, these findings identify convergent molecular signatures across emphysematous and fibrotic lung diseases and suggest that impaired epithelial sialylation may represent a previously underappreciated feature of chronic lung remodeling. (© 2026 Federation of American Societies for Experimental Biology.) |
| References: | Acta Histochem. 2016 Apr;118(3):203-12. (PMID: 26852294) Pharmacol Res. 2026 May;227:108169. (PMID: 41871675) Front Immunol. 2022 Sep 27;13:967357. (PMID: 36248880) Respir Res. 2026 Mar 17;27(1):. (PMID: 41845362) Pharmacol Res. 2016 Jun;108:57-64. (PMID: 27107790) Am J Respir Crit Care Med. 2016 Dec 1;194(11):1392-1402. (PMID: 27310652) Sci Adv. 2020 Jul 08;6(28):eaba1983. (PMID: 32832599) J Clin Invest. 2024 Jul 9;134(18):. (PMID: 38980870) Am J Respir Crit Care Med. 2024 Jan 1;209(1):48-58. (PMID: 37934672) Cancer Lett. 2025 Aug 1;624:217734. (PMID: 40268132) Am J Respir Crit Care Med. 2020 Nov 15;202(10):1430-1444. (PMID: 32602730) Eur Respir Rev. 2026 Mar 25;35(179):. (PMID: 41881452) Am J Respir Crit Care Med. 2024 Aug 15;210(4):401-423. (PMID: 38573068) Respir Res. 2022 Dec 20;23(1):367. (PMID: 36539833) Physiol Rev. 2023 Apr 1;103(2):1059-1093. (PMID: 36201635) Int J Biol Macromol. 2025 May;307(Pt 4):142339. (PMID: 40120906) Inflammation. 2017 Oct;40(5):1487-1496. (PMID: 28534139) Am J Respir Cell Mol Biol. 2023 Apr;68(4):358-365. (PMID: 36473455) Eur Respir J. 2005 Oct;26(4):586-93. (PMID: 16204587) Thorax. 2011 Oct;66(10):918-9. (PMID: 21248320) Eur Respir Rev. 2026 Apr 08;35(180):. (PMID: 41951242) Biomedicines. 2025 Nov 03;13(11):. (PMID: 41301796) Ann Am Thorac Soc. 2015 Mar;12 Suppl 1:S16-20. (PMID: 25830828) Cancers (Basel). 2022 Nov 26;14(23):. (PMID: 36497322) Thorax. 2015 Jan;70(1):48-56. (PMID: 25217476) Cancer Cell Int. 2023 Jul 19;23(1):141. (PMID: 37468844) Nat Genet. 2026 Feb;58(2):376-391. (PMID: 41578022) Cell Death Dis. 2022 May 4;13(5):435. (PMID: 35508454) Transl Res. 2013 Sep;162(3):156-73. (PMID: 23831269) PLoS One. 2024 Feb 27;19(2):e0298573. (PMID: 38412181) Am J Respir Crit Care Med. 2022 Aug 15;206(4):e7-e41. (PMID: 35969190) Cell Death Dis. 2026 Jan 09;17(1):19. (PMID: 41513606) Am J Physiol Lung Cell Mol Physiol. 2023 Nov 1;325(5):L689-L708. (PMID: 37642665) Cell Death Discov. 2024 Sep 30;10(1):415. (PMID: 39349440) Biochim Biophys Acta Mol Basis Dis. 2020 Aug 1;1866(8):165802. (PMID: 32311453) Front Pharmacol. 2024 Sep 24;15:1417834. (PMID: 39380904) J Respir Biol Transl Med. 2025;2(2):. (PMID: 40502298) Nature. 2009 Jun 18;459(7249):1005-9. (PMID: 19421193) BMC Bioinformatics. 2008 Dec 29;9:559. (PMID: 19114008) JAMA Intern Med. 2015 Sep;175(9):1539-49. (PMID: 26098755) Am J Respir Cell Mol Biol. 2022 Jul;67(1):50-60. (PMID: 35468042) Mayo Clin Proc. 2023 Nov;98(11):1685-1696. (PMID: 37923525) |
| Contributed Indexing: | Keywords: ST6GALNAC5; bioinformatics analysis; emphysema; epithelial injury; idiopathic pulmonary fibrosis; sialylation |
| Substance Nomenclature: | EC 2.4.99.- (Sialyltransferases) |
| Entry Date(s): | Date Created: 20260915 Date Completed: 20260915 Latest Revision: 20260917 |
| Update Code: | 20260917 |
| PubMed Central ID: | PMC13576786 |
| DOI: | 10.1096/fj.202602975R |
| PMID: | 42742537 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1530-6860 |
|---|---|
| DOI: | 10.1096/fj.202602975R |